Background/Aims: Ovarian cancer (OC) is a malignant neoplasm of the female reproductive system with a high mortality rate. Identifying useful biomarkers and clarifying the molecular pathogenesis of OC are critical for early diagnosis and treatment. The aim of the study was to identify candidate biomarkers and explore metabolic changes of OC. Methods: A two-stage design was used in our study, with a discovery cohort of OC cases (n = 30) and controls (n = 30) and an independent cohort of cases (n = 17) and controls (n = 18) for validation. The serum metabolic profiling was investigated by ultra-performance liquid chromatography and quadrupole time-of-flight mass spectrometry with positive electrospray ionization. Results: A total of 18 metabolites closely related to OC were identified in the discovery stage, of which 12 were confirmed in the validation cohort. Metabolic pathways in OC related to these biomarkers included fatty acid β-oxidation, phospholipid metabolism, and bile acid metabolism, which are closely related to the proliferation, invasion, and metastasis of cancer cells. Multiple logistic regression analysis of these metabolites showed that 2-piperidinone and 1-heptadecanoylglycerophosphoethanolamine were potential biomarkers of OC, with high sensitivity (96.7%), specificity (66.7%), and area under the receiver operating characteristic curve value (0.894). Conclusion: These findings provide insight into the pathogenesis pathogenesis of OC and may be useful for clinical diagnosis and treatment.
Introduction
Ovarian cancer (OC) is a malignant neoplasm of the female reproductive system, and has a high global mortality rate. Worldwide, approximately 204, 000 new instances of OC are diagnosed each year, with 125, 000 deaths due to OC recorded annually [1] . Early-stage OC is difficult to diagnose due to the scarcity of symptoms, and its etiology is unclear [2] . As such, most patients are diagnosed at an advanced stage and have a low 5-year survival rate [3] . The assay for cancer antigen (CA)125, which is the U.S. Food and Drug Administrationapproved test for OC detection, has high false-positive and -negative rates. Other approaches for detecting OC, for instance, based on carcinoembryonic antigen and human epididymis protein 4 expression, have similar problems [4] . It is therefore necessary to identify more specific biomarkers and catch molecular pathogenesis in order to facilitate the early detection of OC and evaluation of treatment.
Metabolomics is an unbiased analytical method for quantitative and qualitative analyses of metabolites in cells, tissue, or biofluids and their changes in response to pathophysiological stimuli [5] [6] [7] . As products and substrates of metabolism, metabolites play important roles in cellular functions including cell proliferation and apoptosis, which are correlated with the occurrence and development of cancer [8] . Some metabolomic studies of OC have recently been carried out using different techniques. An analysis of serum by liquid chromatography followed by mass spectrometry (LC-MS) identified 7-nor-5β-cholestane-3, 7,12, 24, 25 pentol glucuronide as a potential biomarker for OC that is complementary to CA125 [9] . Another study using 1 H-nuclear magnetic resonance spectroscopy showed that the levels of metabolites such as acetoacetate, acetone, and 3-hydroxybutyrate were elevated in OC patients [10] . Esterified fatty acid (EFA) (C16:0), EFA (C18:0), and free fatty acid (FFA) (C16:0) are also possible biomarkers that were identified by gas chromatographymass spectrometry (GC-MS) analysis, indicating that OC is associated with changes in FA metabolism [11] . Ultra-performance liquid chromatography (UPLC) coupled with MS has higher resolution, sensitivity, and a better metabolite detection range than other analytical techniques and has been widely used to investigate metabolic changes in cancer [12, 13] .
In this study, we used UPLC quadrupole time-of-flight (Q-TOF) tandem MS (MS/MS) to identify potential serum biomarkers and explore metabolic changes in OC in a cohort of patients. The biomarkers were then validated in an independent OC case-control experiment.
Materials and Methods

Study design and biospecimen collection
The two-stage study design included a discovery cohort of OC cases (n = 30) and controls (n = 30), and an independent cohort of cases (n = 17) and controls (n = 18) for validation. OC was confirmed according to the International Federation of Gynecology and Obstetrics (FIGO) staging system [14] , and control subjects were healthy, age-matched volunteers. Exclusion criteria were patients with metabolic, kidney, or liver disease or any other type of cancer. Serum collection and processing were carried out according to standard procedures. All subjects underwent an OC screening test prior to inclusion in the study. Before the screening test, venous blood samples were collected after overnight fasting for 12 h and centrifuged at 3000 × g for 15 min to obtain serum, which was stored at −80°C until analysis. After confirming a diagnosis of OC, the serum was assigned to the OC or control group. Written, informed consent was obtained from all study subjects and the study protocol was approved by the Ethics Committee of the Harbin Medical University (no. 2016005) and was in accordance with the principles outlined in the Declaration of Helsinki.
UPLC-QTOF-MS/MS conditions
UPLC-Q-TOF-MS/MS analysis was performed as previously described [15, 16] with an Acquity UPLC system coupled with a Q-TOF-MS/MS system in electrospray ionization (ESI) in positive mode (Waters, Milford, MA, USA). A 2-μl sample was injected into a BEH-C18 column (4.6 × 50 mm, 1.7 μm; Waters). The mobile phase consisted of solvent A (0.1 % formic acid in water) and solvent B (acetonitrile), and the flow rate was 0.3 ml/min. The initial composition of B was 2% and increased to 20% from 0-1.5 min, then from 20%-70% from 1.5-6 min, 70%-92% from 6-9 min, 92%-98% from 9-15 min, and 98%-98% from 15-16.5 min, followed by re-equilibration to the initial conditions in 4 min. For MS analysis in positive ESI mode, the capillary voltage and sample cone voltage were set at 3000 V and 35 V, respectively. The desolvation temperature was 300°C and the gas flow rate was 600 l/h. The source temperature was set at 100°C and the cone gas flow was 50 l/h. Centroid data were collected from 80-1000 m/z at an acquisition rate of 0.4 with a 0.1-s interscan delay. To ensure accuracy and reproducibility, leucine enkephalin at 200 pg/ml was used as the lock-mass for positive ESI mode ([M+H]+ = 556.2771) via a lock spray interface.
Data processing and biomarkers screening
Data were processed as previously described [15, 16] . The UPLC/Q-TOF MS data were converted in MarkerLynx Application Manager 4.1 SCN 714 (Waters) for analysis. The mass window was set at 0.02 Da, noise elimination level at 10.00, retention time tolerance at 0.01 min, and retention time window at 0.2 min. Data were used up to 16.5 min after the start of the column-washing phase. The resultant three-dimensional matrix consisting of peak indices (retention time-m/z pairs), sample names (observations), and normalized ion intensities for each peak area was exported to EZINFO 2.0 (a component of MarkerLynx) to analyze grouping trends and outliers by the score plot and determine variable importance in projection (VIP) values by partial least squares discriminant analysis (PLS-DA). A principal components analysis (PCA) was used to obtain an overview of data quality assessment. Potential biomarkers were selected according to VIP value (> 1.5) [17] . The goodness-of-fit was quantified by R²Y, while the predictive ability was determined as Q². Using SIMCA-P software (v.11.5; Umetrics AB, Umeå, Sweden), a-cross validation procedure and testing with 800 random permutations was performed to avoid the over-fitting of supervised PLS-DA models. To validate the most significant biomarkers and evaluate classification performance, multiple logistic regression analysis of top candidate metabolites was performed by stepwise selection. The predictive ability of potential metabolic biomarkers and area under the curve (AUC) were evaluated by receiver operating characteristics (ROC) analysis. Sensitivity and specificity were determined according to the maximum value of the Youden index.
The identification of empirical formulae for potential biomarkers was first performed according to accurate mass measurement and the relative intensities of isotopic peaks in high-resolution mass spectra. The MS/MS fragment ion-analysis procedure was facilitated by chemically intelligent peak-matching algorithms using the MassFragment application manager (MassLynx v.4.1, Waters). Briefly, MS/MS spectra of metabolites and exact mass were matched with the structural information of metabolites in the Human 
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Metabolite Database (HMDB) based on parameters such as deviation from calculated mass double bond equivalent and i-fit value (isotopic pattern of the selected ion). The candidate biomarkers were conformed with standard compounds based on retention time and tandem mass spectra. The pathways for biomarkers were interpreted using information from HMDB (http://www.hmdb.ca), Kyoto Encyclopedia of Genes and Genomes (http://www.genome.jp/kegg/) and references.
Statistical analysis
Statistical analysis was performed using SPSS v.13.01S (SPSS Inc., Chicago, IL, USA). Data are presented as the mean ± standard deviation (SD). An independent samples t-test was used to analyze differences between groups. P values were two-tailed and a value < 0.05 was considered as significant.
Results
Clinical characteristics of study subjects
In this study, we recruited a discovery cohort of 30 OC patients and 30 healthy controls and a validation cohort of 17 OC patients and 18 healthy controls. There were no significant differences in age and weight between OC and control groups. OC patients had higher serum levels of CA125 than healthy individuals. OC was classified into four stages according to FIGO staging system (Table 1 ).
Data quality assessment of metabolomics platform
An overview of the quality of the analytical run was obtained by PCA of the sample and QC injections dataset. The results showed that the QC samples were tightly clustered in the score plots ( Fig. 1 , red crosses). In the discovery samples, the relative (R) SDs of retention time and peak intensity ranged from 0.07% to 0.63% and 4.23% to 6.56%, respectively. In the validation samples, the RSDs of retention time and peak intensity ranged from 0.03% to 0.67% and 2.36% to 8.82%, respectively (Table 2) . These values were all lower than 10%, implying that the results had excellent repeatability. 
Serum metabolite profiling
Representative single UPLC-Q-TOF/MS base peak intensity chromatograms of an OC patient and a healthy control are shown in Fig. 2 . A total of 6948 ions (peaks) were assessed in the discovery analysis. Both the unsupervised (PCA) and supervised (PLS-DA) methods were used to evaluate global metabolic alterations in healthy controls and OC patients, and corresponding VIP values were also estimated in the PLS-DA model. The PLS-DA score plots revealed that the OC patients and healthy subjects could be separated into distinct clusters according to differences in serum metabolite composition, and that the parameters of the PLS-DA model-including the values of R 
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
ESI mode) were all > 0.5 ( Fig. 3A) , implying that the model was a good fit. In addition, the permutation test of the established PLS-DA model showed that all permuted R 2 and Q 2 values were lower than the original points to the right and that the Q 2 regression line had a negative intercept (Fig. 3B) , indicating the feasibility of the PLS-DA model.
Identification of differential metabolites
The VIP values (VIP > 1.5) obtained from the established PLS-DA model and P values (P < 0.05) obtained from the t-test of metabolites in the two groups were used as a basis for screening candidate metabolites. A total of 18 metabolites were identified including 2-piperidinone, eicosadienoic acid, 7-ketodeoxycholic acid, varanic acid, 1-heptadecanoylglycerophosphoethanolamine, lysophosphatidylcholine (lysoPC) (P-16:0), lysoPC ( (Table 3 ). More detailed information on each metabolite is provided in Table 4 . Five of the 18 metabolites including PC (14:1/22:2), eicosadienoic acid, varanic acid, lysoPC (15:0), and lysoPE (0:0/20:0) were Table 2 . Repeatability of experimental method in discovery and validation studies. RT = retention time; RSD = relative standard deviation 
Fig. 2
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identified using standard compounds. Chemical structures and mass fragment information on the principal metabolites are shown in Fig. 4 . Other metabolites were confirmed by MS/ MS fragment ion-analysis and using a library database, since no authentic standards were commercially available ( Fig. 5 and 6 ).
Validation study of top metabolites
An independent case-control experiment was performed to validate the 18 metabolites obtained in the discovery analysis. As in the latter, the experiment showed good reproducibility ( Table 2) . Differences in the abundance of the 18 metabolites between OC patients and controls in the validation group were evaluated (Table 4) ; the results showed that 12 of the metabolites differed significantly, including 2-piperidinone, eicosadienoic acid, 7-ketodeoxycholic acid, varanic acid, 1-heptadecanoylglycerophosphoethanolamine, 2-hexaprenyl-3-methyl- Cell
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(AUC > 0.6). In particular, 2-piperidinone and 1-heptadecanoylglycerophosphoethanolamine showed excellent predictability of disease status (AUC > 0.75). The sensitivity, specificity, and best cutoff according to the maximum value of the Youden index were also determined (Table 5) .
Multiple logistic regression analysis
To identify the most representative biomarkers for distinguishing OC patients from healthy people, a multiple logistic regression model was established by stepwise selection. The model was first established with 12 metabolites in the discovery samples after controlling for age. Two metabolites, i.e., 2-piperidinone (β = −0.0119, P < 0.05) and 1-heptadecanoylglycerophosphoethanolamine (β = 0.0955, P < 0.05), were also included in the model generated with the independent validation samples (2-piperidinone, β = −0.0352, P < 0.05 and 1-heptadecanoylglycerophosphoethanolamine, β = 0.0992, P < 0.05) ( Table 6 ). We calculated the sensitivity, specificity, and AUC of the regression model and the results showed that the model fit well with the discovery sample (AUC = 0.894; sensitivity = 96.7%; specificity = 66.7%) and validation sample (AUC = 0.956; sensitivity = 93.3%; specificity = 80.0%) ( Table 7 and Fig. 7 ). Table 6 . Multiple logistic regression models for the discovery and validation cohorts. SE = standard error * R2 = 0.606 † R2 = 0.799 
Discussion
In this study, we carried out a metabolomics analysis of serum samples from OC patients to identify potential biomarkers and determined that 18 metabolites best characterized disease status, of which 12 were validated in an independent case-control study. Multiple logistic regression analysis of the 12 metabolites showed that two, 2-piperidinone and 1-heptadecanoylglycerophosphoethanolamine, were significant predictors of OC.
Metabolic pathway analysis of the 12 identified metabolites showed that they were closely associated with OC. The 2-piperidinone is a derivative of piperidine, which is an organic compound that affects the activity and expression of cytochrome P450 (CYP)2E1, and thus indirectly influences oxidative stress and metabolic activation of low-molecular weight toxins [18] . CYP2E1 is associated with the metabolism of a variety of compounds including 1, 3-butadiene, nitrosamines, benzene, and other carcinogens, and free radicals [19] . CYP2E1 is implicated in human malignancies including gastrointestinal and respiratory tumors [20, 21] , and CYP2E1 gene polymorphisms are associated with the occurrence of breast and cervical cancers in females [22, 23] . Another study showed that 2-piperidone is a specific marker of OC [24] , which is in accordance with our findings.
Eicosadienoic acid is an omega-6 fatty acid. The n-6 PUFA is a specific substrate for 5-lipoxygenase (5-LOX) and cyclooxygenase (COX)-2. Studies have shown that n-6 PUFA interacts with 5-LOX and COX-2 on the cell membrane to generate arachidonic acid compounds such as prostaglandin E2 and 12-hydroxy-carbon tetracon acid, which are known to promote cancer. Elevated levels of 5-LOX and COX-2 in breast cancer cells enhance the proliferation, invasion, and migration of cancer cells by activating G protein-coupled receptors (GPCRs), promoting tumor angiogenesis, and inhibiting apoptosis and the immune system [25] . Additionally, n-6 fatty acid-derived metabolites promote angiogenesis, a necessary step for tumor growth and metastasis, by inducing the expression of growth factors [26] ; n-6 fatty acids have also been implicated in the progression of breast [27] and prostate [28] cancers.
The compound 1-heptadecanoylglycerophosphoethanolamine, lysoPC (15:0), LysoPE (0:0/20:0), and PC (14:1/22:2) are phosphate esters like lysophosphatidic acid (LPA), a natural phospholipid that promotes the invasion, metastasis, and proliferation of cancer A previous study showed that LPA can induce OC cell proliferation and adhesion junction breakdown via activation of Src family kinases [29] . LPA stimulates SKOV3 OC cell proliferation and inhibits their apoptosis through activation of mitogen-activated protein kinase signaling [30] . Another study demonstrated that LPA induces the migration, invasion, and proliferation of OC cells through regulation of vascular endothelial growth factor, urokinase plasminogen activator, matrix metalloproteinases, interleukin-8, COX-2, interleukin-6, CXC motif chemokine ligand 12/CXC receptor 4, cyclin D1, Hippo-Yap, and growth-regulated oncogene α [31] . Lactosylceramide and galabiosylceramide are ceramides, which are potent suppressors of neoplasms that promote apoptosis, autophagy, and cell cycle arrest [32] . One study reported that ceramide glycosylation affected cancer development and progression by regulating gene expression, restoring p53 expression via RNA splicing, and downregulating multidrug-resistant 1 via cSrc/β-catenin signaling [33] . It has also been suggested that fatty acid chain length, subcellular localization, and/or direct downstream targeting of de novogenerated ceramides have distinct and opposite effects in tumor promotion/suppression [34] .
Ketodeoxycholic acid and varanic acid are bile acids whose accumulation in blood and tissues is controlled by various mechanisms owning to their toxicity [35, 36] . Bile acids such as chenodeoxycholic acid (CDCA) and DCA are cytotoxic to OC cells and induce their apoptosis [37] . Most bile acids are cytotoxic to a broad range of tumor cells and are highly selective for HepG2 cells, with CDCA exhibiting especially high selectivity for these cells [38] . A reduction in CDCA concentrations was found to accelerate human endometrial cancer cell growth by inducing an increase in cyclin D1 protein and mRNA expression via activation of GPCR-dependent pathways [39] . The close relationship between bile acids and colorectal cancer [40] and gastric cancer [41] in females provide support for bile acid levels as a predictor of OC.
The 2-hexaprenyl-3-methyl-6-methoxy-1, 4 benzoquinone is a polyprenyl benzoquinone that is involved in the ubiquinone (CoQ) biosynthesis pathway. CoQ10 influences the expression of genes involved in cell signaling, metabolism, and trafficking, which may in turn indirectly promote cancer onset [42] . Epidemiological studies have shown that low plasma concentrations of CoQ10 may be caused by an inadequate dietary intake or reduced endogenous biosynthesis resulting from increased utilization of reactive oxygen species induced by oxidative stress [43] . DG (14:0/20:0/0:0) is a diglyceride or a diacylglycerol (DAG) composed of two fatty acid chains covalently bound to a glycerol molecule via ester linkages. Diglycerides play an important role in signal transduction and lipid metabolism in mammalian cells [44] . Diacylglycerol kinase (DGK) α is one of 10 DGK family members that convert diglycerides into phosphatidic acid, which along with DAG is a lipid second messenger in the plasma membrane. DGKα inhibition can promote T cell activation and boost cancer immunotherapy by preventing angiogenesis and causing damage to cancer cells [45] .
Conclusion
In summary, we identified 12 biomarkers that may be associated with abnormal fatty acid β-oxidation and phospholipid and bile acid metabolism in OC using a UPLC/Q-TOF MS-based metabolomics strategy and multivariate data analysis. Two of the identified metabolites (2-piperidinone and 1-heptadecanoylglycerophosphoethanolamine) were validated in a multiple logistic regression model. These findings provide novel insight into the pathogenesis of OC, and may be applicable to its clinical diagnosis and treatment.
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